Phaseline

Targets › LHRH

LHRH (Progonadoliberin-1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Nov 2027.

[Gonadoliberin-1]: Hypothalamic decapeptide hormone that functions as the master regulator of the hypothalamic-pituitary-gonadal axis. Released in a pulsatile manner from hypothalamic neuron terminals into the hypophyseal portal circulation, it acts on pituitary gonadotrope cells by binding to and activating its cognate G protein-coupled receptor GNRHR, thereby stimulating the synthesis and secretion of the…. (UniProt, P01148)

Open in Phaseline: the race on LHRH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Jonsson Comprehensive Cancer CenterLuteinizing hormone-releasing hormone agonist or gonadotropin-releasing hormone
Androgen deprivation via LHRH/GnRH agonist or antagonist combined with androgen receptor a
LHRH, GNRHPhase 2PSA Level Greater Than 0.03Nov 2027

Conditions

PSA Level Greater Than 0.03 (1)

Modalities

small molecule (1)

Companies

Jonsson Comprehensive Cancer Center (1)

Related targets

GNRH (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.